IS7173A - Líffræðilegar afurðir - Google Patents

Líffræðilegar afurðir

Info

Publication number: IS7173A
Authority: IS; Iceland
Prior art keywords: disclosed; cdr; antibody; antibody molecules; biological products
Prior art date: 2001-10-10

Application number

IS7173A

Other languages

English (en)

Inventor

George Popplewell Andrew

Peter Tickle Simon

Zinkewich-Peotti Karen

Kendall Morrison Robert

Original Assignee

Celltech R & D Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2004-03-05

Publication date

2004-03-05

2004-03-05 Application filed by Celltech R & D Limited filed Critical Celltech R & D Limited

2004-03-05 Publication of IS7173A publication Critical patent/IS7173A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Jellies, Jams, And Syrups (AREA)
Bakery Products And Manufacturing Methods Therefor (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

IS7173A 2001-10-10 2004-03-05 Líffræðilegar afurðir IS7173A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0124317.9A GB0124317D0 (en)	2001-10-10	2001-10-10	Biological products
PCT/GB2002/004619 WO2003031475A2 (en)	2001-10-10	2002-10-10	Antibodies against kdr, their production and uses

Publications (1)

Publication Number	Publication Date
IS7173A true IS7173A (is)	2004-03-05

Family

ID=9923562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7173A IS7173A (is)	2001-10-10	2004-03-05	Líffræðilegar afurðir

Country Status (24)

Country	Link
US (2)	US7452976B2 (is)
EP (1)	EP1438340B1 (is)
JP (2)	JP4323312B2 (is)
KR (2)	KR101018908B1 (is)
CN (1)	CN1568331A (is)
AT (1)	ATE482234T1 (is)
AU (1)	AU2002334135B8 (is)
BR (1)	BR0212756A (is)
CA (1)	CA2458464A1 (is)
CO (1)	CO5580838A2 (is)
DE (1)	DE60237778D1 (is)
DK (1)	DK1438340T3 (is)
EA (1)	EA010970B1 (is)
ES (1)	ES2351208T3 (is)
GB (1)	GB0124317D0 (is)
HU (1)	HUP0401618A3 (is)
IL (1)	IL160849A0 (is)
IS (1)	IS7173A (is)
MX (1)	MXPA04003274A (is)
NO (1)	NO20040987L (is)
NZ (1)	NZ532758A (is)
PL (1)	PL208848B1 (is)
WO (1)	WO2003031475A2 (is)
ZA (1)	ZA200401910B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0129105D0 (en) *	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR101215218B1 (ko)	2003-07-22	2012-12-26	바이엘 파마 악티엔게젤샤프트	Ｒｇ１ 항체 및 그의 용도
GB0329825D0 (en) *	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
GEP20105059B (en)	2004-07-26	2010-08-10	Biogen Idec Inc	Anti-cd154 antibodies
US7785591B2 (en)	2004-10-14	2010-08-31	Morphosys Ag	Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
WO2006099747A1 (en) *	2005-03-25	2006-09-28	National Research Council Of Canada	Method for isolation of soluble polypeptides
GB0520169D0 (en) *	2005-10-04	2005-11-09	Celltech R&D Ltd	Biological products
DK1976877T4 (en) *	2005-11-30	2017-01-16	Abbvie Inc	Monoclonal antibodies to amyloid beta protein and uses thereof
EP1954718B1 (en)	2005-11-30	2014-09-03	AbbVie Inc.	Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
EP2046833B9 (en)	2006-07-14	2014-02-19	AC Immune S.A.	Humanized antibody against amyloid beta
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
BR122020022640B1 (pt)	2007-03-22	2022-03-29	UCB Biopharma SRL	Molécula de dna codificando proteínas de ligação a cd154, vetor, célula hospedeira e método de produção das referidas proteínas
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
PL2238166T3 (pl)	2007-10-05	2014-07-31	Genentech Inc	Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
SG10201505038TA (en) *	2009-02-17	2015-07-30	Ucb Biopharma Sprl	Antibody molecules having specificity for human ox40
CN101531718B (zh) *	2009-04-22	2011-11-02	中国人民解放军南京军区军事医学研究所	抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
PL2993231T3 (pl)	2009-09-24	2019-01-31	Ucb Biopharma Sprl	Szczep bakteryjny do ekspresji rekombinowanego białka mający degp pozbawione aktywności proteazowej przy zachowaniu aktywności białka opiekuńczego i nokauty genów tsp i ptr
GB201000587D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial hoist strain
GB201000590D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial host strain
GB201000591D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial hoist strain
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
GB201012599D0 (en)	2010-07-27	2010-09-08	Ucb Pharma Sa	Process for purifying proteins
RU2607368C2 (ru)	2010-07-30	2017-01-10	Ац Иммуне С.А.	Безопасные и функциональные гуманизированные антитела
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
HUE035674T2 (en)	2011-07-13	2018-05-28	Ucb Biopharma Sprl	Bacterial host strain expressing recombinant dsbc
CA2854153A1 (en)	2011-11-02	2013-05-10	Apexigen, Inc.	Anti-kdr antibodies and methods of use
UA112203C2 (uk)	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
BR112014020697B1 (pt)	2012-02-24	2024-01-09	Alteogen Inc	Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
GB201208367D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Biological product
DK2924052T3 (da)	2012-11-21	2019-09-30	Pharmabcine Inc	Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
JP7303182B2 (ja)	2017-04-21	2023-07-04	メリタスエルエルシー	糖尿病関連用途のための方法及び抗体
EP3853377A4 (en)	2018-09-19	2022-10-05	Totient, Inc.	ANTIBODY COMPOSITIONS ASSOCIATED WITH CANCER AND METHODS OF USE
WO2020132654A1 (en) *	2018-12-20	2020-06-25	Albert Einstein College Of Medicine	Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en)	1989-02-10	1989-03-30	Celltech Ltd	Chemical compounds
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
CN1173991C (zh)	1992-11-13	2004-11-03	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k-1
DE19638745C2 (de)	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6133426A (en) *	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
US6204011B1 (en)	1997-06-18	2001-03-20	Merck & Co., Inc.	Human receptor tyrosine kinase, KDR
EP1086705A4 (en)	1998-05-20	2002-02-06	Kyowa Hakko Kogyo Kk	INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
AU3475100A (en) *	1999-01-29	2000-08-18	Imclone Systems Incorporated	Antibodies specific to kdr and uses thereof

2001
- 2001-10-10 GB GBGB0124317.9A patent/GB0124317D0/en not_active Ceased
2002
- 2002-10-10 EA EA200400519A patent/EA010970B1/ru not_active IP Right Cessation
- 2002-10-10 DE DE60237778T patent/DE60237778D1/de not_active Expired - Lifetime
- 2002-10-10 EP EP02800666A patent/EP1438340B1/en not_active Expired - Lifetime
- 2002-10-10 NZ NZ532758A patent/NZ532758A/en not_active IP Right Cessation
- 2002-10-10 MX MXPA04003274A patent/MXPA04003274A/es active IP Right Grant
- 2002-10-10 ES ES02800666T patent/ES2351208T3/es not_active Expired - Lifetime
- 2002-10-10 US US10/492,228 patent/US7452976B2/en not_active Expired - Fee Related
- 2002-10-10 JP JP2003534457A patent/JP4323312B2/ja not_active Expired - Fee Related
- 2002-10-10 KR KR1020047005051A patent/KR101018908B1/ko not_active Expired - Fee Related
- 2002-10-10 AT AT02800666T patent/ATE482234T1/de not_active IP Right Cessation
- 2002-10-10 BR BR0212756-3A patent/BR0212756A/pt not_active IP Right Cessation
- 2002-10-10 IL IL16084902A patent/IL160849A0/xx not_active IP Right Cessation
- 2002-10-10 HU HU0401618A patent/HUP0401618A3/hu unknown
- 2002-10-10 AU AU2002334135A patent/AU2002334135B8/en not_active Ceased
- 2002-10-10 WO PCT/GB2002/004619 patent/WO2003031475A2/en not_active Ceased
- 2002-10-10 CN CNA028202104A patent/CN1568331A/zh active Pending
- 2002-10-10 PL PL370344A patent/PL208848B1/pl not_active IP Right Cessation
- 2002-10-10 KR KR1020077023689A patent/KR20070116110A/ko not_active Ceased
- 2002-10-10 DK DK02800666.6T patent/DK1438340T3/da active
- 2002-10-10 CA CA002458464A patent/CA2458464A1/en not_active Abandoned
2004
- 2004-03-05 IS IS7173A patent/IS7173A/is unknown
- 2004-03-08 NO NO20040987A patent/NO20040987L/no not_active Application Discontinuation
- 2004-03-09 ZA ZA200401910A patent/ZA200401910B/en unknown
- 2004-05-06 CO CO04041969A patent/CO5580838A2/es not_active Application Discontinuation
2007
- 2007-10-30 US US11/928,880 patent/US7842787B2/en not_active Expired - Fee Related
2008
- 2008-11-18 JP JP2008294819A patent/JP2009108086A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
BR0212756A (pt)	2004-11-16
KR101018908B1 (ko)	2011-03-02
EP1438340B1 (en)	2010-09-22
CA2458464A1 (en)	2003-04-17
CN1568331A (zh)	2005-01-19
ATE482234T1 (de)	2010-10-15
US20050181448A1 (en)	2005-08-18
WO2003031475A3 (en)	2004-03-25
DE60237778D1 (de)	2010-11-04
MXPA04003274A (es)	2004-07-08
IL160849A0 (en)	2004-08-31
DK1438340T3 (da)	2010-11-22
EA010970B1 (ru)	2008-12-30
US7452976B2 (en)	2008-11-18
ZA200401910B (en)	2005-03-09
NO20040987L (no)	2004-05-10
PL370344A1 (en)	2005-05-16
EA200400519A1 (ru)	2004-12-30
KR20040097983A (ko)	2004-11-18
EP1438340A2 (en)	2004-07-21
HUP0401618A3 (en)	2012-03-28
NZ532758A (en)	2008-04-30
AU2002334135B2 (en)	2009-01-08
AU2002334135B8 (en)	2009-01-29
JP2009108086A (ja)	2009-05-21
US7842787B2 (en)	2010-11-30
GB0124317D0 (en)	2001-11-28
JP2005516590A (ja)	2005-06-09
ES2351208T3 (es)	2011-02-01
US20090269840A1 (en)	2009-10-29
KR20070116110A (ko)	2007-12-06
WO2003031475A8 (en)	2004-10-14
WO2003031475A2 (en)	2003-04-17
JP4323312B2 (ja)	2009-09-02
CO5580838A2 (es)	2005-11-30
HUP0401618A2 (hu)	2004-11-29
PL208848B1 (pl)	2011-06-30

Publication	Publication Date	Title
IS7173A (is)	2004-03-05	Líffræðilegar afurðir
LTPA2017044I1 (lt)	2018-01-10	Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
MY136603A (en)	2008-10-31	Biological products
MXPA02011656A (es)	2004-07-30	Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
EA200300246A1 (ru)	2003-08-28	Ген и белок, ассоциированные с шизофренией
WO2002093519A3 (de)	2003-10-30	Humane hochaffine antikörperfragmente gegen essentielle proteine (ns3) von hepatitis-c-virus